Objective responses to first-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial
ICON8 was an international, multicentre, randomised, phase 3 trial done across 117 hospitals in the UK, Australia, New Zealand, Mexico, South Korea, and Ireland. Median follow-up was 29.5 months for the neoadjuvant chemotherapy followed by DPS population. Median progression-free survival was 14.4 months for patients with a RECIST. complete or partial response.
